Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw ...

4 August 2026 · By · Wire by Fusion42

Published

4 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at raps.org →

◆ Verified

Fusion42 · 5 August 2026 · Fusion42 review

Eli Lilly is expanding patient access to its unapproved obesity drug, creating broader opportunities for treatment. Jazz Pharmaceuticals will withdraw the second-line small cell lung cancer indication for Zepzelca, impacting treatment options in that area.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must adjust growth plans as Eli Lilly opens access to patients for its obesity drug, creating a new market dynamic. Meanwhile, withdrawing Zepzelca's second-line lung cancer use sharpens focus on alternative treatments and competition.

◆ Coverage

1 source · 4 Aug 2026

◆ Related on Wire

◆ Topics

Biotechobesity-drugsexpanded-accessregulatory-withdrawalsmall-cell-lung-cancerFDA